ABOUT US OUR SCIENCE OUR PRODUCT NEWS CONTACT Expanded Access Policy At Avelas Biosciences, we are committed to developing products that bring new, innovative therapies, like pegloprastide (AVB-620), to patients with serious or life-threatening illnesses or conditions. Avelas is developing pegloprastide to improve the ability of surgeons to identify cancerous tissue on the surface of tissue during breast cancer surgery. Pegloprastide must be used in conjunction with a specific imaging device to visualize potentially cancerous tissue during surgery. At this time, Avelas does not offer an expanded access program and is not accepting expanded access requests for investigational products, such as pegloprastide. Avelas’ current focus and priority is to complete the product development program for its investigational product(s), such as pegloprastide, in order to obtain the required safety and efficacy data needed for regulatory approval. We believe that focusing our resources on our clinical trial program is the best path forward to bring our investigational product(s) to patients as quickly and safely as possible. As we continue to develop investigational product(s), we will review our expanded access policy for investigational product(s) and may make updates to this policy. Patients can gain access to our investigational product(s), such as pegloprastide, by participating in a clinical trial. If you or someone you know would like to learn more about Avelas Biosciences’ clinical trials, we encourage you to view our trials at www.clinicaltrials.gov. If you have additional questions about Avelas’ expanded access policy, please email us at info@avelasbio.com. HOME ABOUT US OUR SCIENCE OUR PRODUCT NEWS CONTACT Copyright © Avelas Biosciences | Website by AshWebStudio

ABOUT US OUR SCIENCE OUR PRODUCT NEWS CONTACT Intraoperative Imaging Device Avelas’ Intraoperative Imaging Device simultaneously images two far red and near infra-red wavelengths to realize the advantages of ratiometric fluorescent readout of pegloprastide for real-time cancer detection. Pegloprastide’s ratiometric readout attenuates common artifacts of fluorescent imaging, including differences in drug concentration and distance of the camera from the tissue area of interest. Pegloprastide is the only fluorescence-based clinical cancer detection product that utilizes ratiometric imaging to provide more accurate and actionable information during a procedure. Avelas’ device has a wide field of view (~10 cm) and provides a rapid assessment of tissue (~100 ms). Avelas’ imaging system may be used on various sample types, including excised specimen, shave margins, and in vivo in a patient’s cavity. Display overlay software provides an objective prediction of cancer in real-time to surgeons, giving them the necessary information to make clinical decisions to improve outcomes for patients. HOME ABOUT US OUR SCIENCE OUR PRODUCT NEWS CONTACT Copyright © Avelas Biosciences | Website by AshWebStudio